CheckMate 067: Nivolumab + Ipilimumab and Nivolumab Alone Superior to Ipilimumab Alone in Previously Untreated Advanced Melanoma

May 29-June 2, 2015; Chicago, Illinois
Data from this large phase III trial suggest that the combination of nivolumab + ipilimumab offers better efficacy vs ipilimumab alone, but also better efficacy vs nivolumab alone, particularly for patients whose tumors are low in PD-L1 expression.
Format: Microsoft PowerPoint (.ppt)
File Size: 775 KB
Released: June 2, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for ALL

Jae H. Park, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

From Clinical Care Options (CCO), video featuring expert insights on the integration of CAR T-cell therapy into community care

person default Caron A. Jacobson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2021 Expired: June 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue